In this study, TPP‐LND@Lip nanoparticles are established to sensitize lung cancer radiotherapy by reversing the hypoxic microenvironment of tumors to generate more DNA damage and reducing the expression of programmed death ligand‐1 (PD‐L1) via enhancing the adenosine 5′‐monophosphate‐activated protein kinase activation. This evidence concerns the gene CD274 and lung carcinoma.